Trexquant Investment LP Has $3.73 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Trexquant Investment LP lifted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 235.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,067 shares of the biotechnology company's stock after purchasing an additional 19,010 shares during the period. Trexquant Investment LP's holdings in Ascendis Pharma A/S were worth $3,726,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ASND. Groupama Asset Managment bought a new position in Ascendis Pharma A/S during the 3rd quarter worth $60,000. Frazier Life Sciences Management L.P. acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $19,908,000. American Century Companies Inc. increased its position in Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock worth $56,072,000 after acquiring an additional 60,548 shares during the period. Artisan Partners Limited Partnership increased its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after acquiring an additional 39,309 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Ascendis Pharma A/S by 94.4% in the 4th quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after purchasing an additional 37,593 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock traded up $7.66 during midday trading on Friday, hitting $150.99. 426,300 shares of the company traded hands, compared to its average volume of 478,482. The stock has a market cap of $9.16 billion, a price-to-earnings ratio of -21.27 and a beta of 0.54. The firm's fifty day moving average price is $148.33 and its 200-day moving average price is $137.70. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ASND. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Cantor Fitzgerald raised their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 25th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a report on Tuesday, February 18th. Evercore ISI increased their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Finally, JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.